

**SYNTHESES OF TRANS- AND CIS- $\alpha$ -(CARBOXYCYCLOPROPYL)GLYCINES. NOVEL NEUROINHIBITORY  
AMINO ACIDS AS L-GLUTAMATE ANALOGUE**

Keiko Yamanoi and Yasufumi Ohfune\*

*Suntory Institute for Bioorganic Research, Shimamoto-cho, Mishima-gun, Osaka 618, Japan*

Kazuko Watanabe, Philipp Novales Li, and Hiroshi Takeuchi

*Department of Physiology, School of Medicine, Gifu University,*


*Gifu 500, Japan*

**Summary:** Four diastereoisomers of  $\alpha$ -(carboxycyclopropyl)glycines were synthesized from (2*S*)-2-amino-3-butanol via an inter- or intramolecular cyclopropanation. Results of neurobiological assay using a  $\beta$ -hydroxy-L-glutamate sensitive neuron indicated clear conformation-activity relationship between these synthetic L-glutamate analogues.

Glutamate receptors in the central nervous systems have attracted much attention in the life sciences. Recently, several glutamate analogues such as kainic acid<sup>1</sup> and domoic acid,<sup>1b,2</sup> possessing an L-glutamate moiety as a part of their structures, have become important tools in neuropharmacology because of their potent agonistic behavior. While structure-activity relationship between L-glutamic acid and these agonists cannot yet be clarified to date, it has been proposed that L-glutamic acid adopts a specific conformation (extended or folded) when it interacts with the receptors of some neurons.<sup>3</sup>

Recently, Takeuchi et al. reported pharmacological studies using a variety of L-glutamate analogues on identifiable giant neurons, sensitive to threo and/or erythro  $\beta$ -hydroxy-L-glutamic acid (L-BHGA), of an African giant snail (*Achatina fulica* Ferussac).<sup>4</sup> Through these studies, recognition of the  $\beta$ -configuration of L-BHGA by the receptors was observed. We focused on explaining the role of the hydroxyl group in fixing the conformation and/or as a H<sup>+</sup> donor-acceptor. As shown in **Scheme I**, we believed

**Scheme I**




that four BHGA conformational-configurational isomers **2a-2d** would be mimicked by four  $\alpha$ -(carboxycyclopropyl)-glycines (CCG) **1a-1d**. CCGs **1a** and **1c** have been isolated from the *Spindaceae* family by Fowden et al.<sup>5,6</sup> We wish to report here the stereoselective synthesis of naturally occurring cis-CCG **1c** and the simple syntheses of the four isomers **1a-1d** from chiral 2-amino-3-butenol **3**.<sup>7</sup> The preliminary bioassay results using L-BHGA sensitive neurons are also described.

For the synthesis of cis-CCG **1c**, we planned to use the intramolecular cyclopropanation of the diazoamide **4c** as the key step. The *N*-*tert*-butoxycarbonyl (*t*-Boc) group of the dipeptide **4a**, prepared from (2*S*)-2-amino-3-butenol **3a** in two steps [(i) *N*-*t*-Boc-glycyl-*O*-succinate and (ii) 2,2-dimethoxypropane/*dl*-camphorsulfonic acid (CSA), 62%], was removed selectively with trimethylsilyl trifluoromethanesulfonate (TMSOTf)/2,6-lutidine<sup>8</sup> to give exclusively the desired amine **4b**. Sequential treatments of the amine with (i) NaNO<sub>2</sub>/pH 3 buffer and (ii) catalytic palladium (II) acetate yielded the cycloadduct **5a** and **5b** (43%, **5a/5b**=6/1). The major isomer, having desired stereochemistry, was purified by SiO<sub>2</sub> column chromatography and was converted to the *N*-*t*-Boc derivative **6** by the following sequence of reactions: (i) removal of the *N,O*-acetonide with 60% AcOH, (ii) hydrolysis of the amide with 0.5 N NaOH, (iii) protection of the resulting amine with a *t*-Boc group, and (iv) Jones oxidation (59% from **5a**). Finally, deprotection with trifluoroacetic acid (TFA) provided the desired CCG **1c** (mp 192-197 °C, [ $\alpha$ ]<sub>D</sub><sup>25</sup> +20.8° (c 0.52, H<sub>2</sub>O)), identical in all respects with natural **1c**.<sup>5</sup>

Intermolecular cycloaddition of ethyl diazoacetate with the silyl ether **3b** gave a mixture of cycloadducts **7a-7d** in 41% yield (**7a/7b/7c/7d** = 1.2/3.5/1/1; 58% of the starting **3b** was recovered and recycled). After removal of the silyl group with CSA/EtOH, **7b** (Rf 0.46 in ether/hexane=3/1) and **7c** (Rf 0.30) were separated from the above mixture by medium pressure column chromatography. Since **7a** and **7d** were found to have the same Rf value (0.38), these were treated with CSA/CH<sub>2</sub>Cl<sub>2</sub> to give a separable mixture of **7a** and  $\delta$ -lactone **7f** (Rf 0.30 in ether/hexane=3/1). Hydrolysis and esterification of **7f** provided **7e** quantitatively. Thus, each of the isomers **7a-7c** and **7e** were converted to the desired **1a-1d**<sup>9,10</sup> by the following sequence of reactions: (i) Jones oxidation, (ii) 0.5 N NaOH, and (iii) TFA (ca. 80%, 3 steps).

These synthetic CCGs **1a-1d** were submitted for neurobiological assay using the periodically oscillating neuron (PON), which is sensitive to  $\beta$ -hydroxy-L-glutamic acid, of an African giant snail.<sup>4</sup> In PON receptors, inhibitory effects by L-BHGA were observed: the minimum effective concentration (MEC) of erythro-L-BHGA is ca. 10<sup>-5</sup> M, and that of the threo isomer is ca. 10<sup>-4</sup> M. The effective potency quotient (EPQ) was calculated: (MEC of erythro-L-BHGA)/(MEC of the substrate). As shown in **Scheme I**, **1a** can be viewed as being conformationally fixed in the erythro-extended conformation **2a**. Likewise, **1b-1d**



<sup>a</sup> (a) (1) *N*-*t*-Boc-Glycyl-O-Succinate,  $Et_3N$ , tetrahydrofuran,  $-20\text{ }^\circ\text{C}$ , 3 h; (2) 2,2-dimethoxypropane, acetone, CSA,  $80\text{ }^\circ\text{C}$ , 16 h; (b) (1) 1.5 equiv TMSOTf, 2.0 equiv 2,6-lutidine, room temperature, 15 min; (2)  $NaNO_2$ , citric acid, pH 3,  $0\text{ }^\circ\text{C}$ ; (c) 0.05 equiv  $Pd(OAc)_2$ , toluene,  $80\text{ }^\circ\text{C}$ , 2h; (d) 60% acetic acid, room temperature, 16 h; (e) 0.5 N NaOH,  $70\text{ }^\circ\text{C}$ , 4 h; Di-*tert*-butyl dicarbonate,  $Et_3N$ , dioxane- $H_2O$  (1:1), room temperature, 16 h; (g) Jones reagent, acetone,  $0\text{ }^\circ\text{C}$ , 14 h. (h) (1) TFA,  $0\text{ }^\circ\text{C}$ , 30 min; (2) Dowex 50Wx4 (elution with 3%  $NH_3$ ; (3) 1 N HCl, pH 3.0; (i) (1) ethyl diazoacetate, 0.05 equiv  $Pd(OAc)_2$ , room temperature, 4 h; (2) CSA, EtOH, room temperature, 16 h.

corresponds to **2b-2d**. Bioassay results are summarized as follows: erythro-L-BHGA **2a** or **2c** (EPQ=1), threo-L-BHGA **2b** or **2d** (0.1), **1a** (30), **1b** (0.03), **1c** (no effect), and **1d** (3). Since the erythro-extended isomer **1a** had marked effect and the threo **1b** and the folded **1c** showed almost no effect, this suggests that the erythro configuration and the extended conformation of **1a** are recognized by the receptor. Therefore, we assume that an active conformation of the erythro-L-BHGA would be the extended **2a** which is mimicked by the erythro-extended **1a**: the role of the  $\beta$ -hydroxyl group of erythro-L-BHGA is to fix the glutamate chain in the extended conformation when it interacts with the receptor. On the other hand, the threo-folded **1d** (EPQ=3) which mimics the threo-folded **2d** exhibited a marked effect compared with that of threo-L-BHGA **2b** or **2d** (EPQ=0.1), while the extended **1b** and the erythro **1c** had almost no effect. We propose the presence of a distinct threo-folded sensitive receptor on PON where the extended conformation is recognized: the  $\beta$ -hydroxyl group of threo-L-BHGA would fix the glutamate chain in the folded conformation (see, **2d**).<sup>11,12</sup>

We hope these compounds will be useful tool to investigate the nature of L-glutamate receptors in view of conformation-activity relationship not only in the molluscan nervous systems but also in mammalian brains. Further studies related this work using **1a-1d** and other glutamate analogues on other neurons are in progress.

**Acknowledgement:** We thank Professor Koji Nakanishi, Director, for continuous encouragement.

*References and Note*

1. (a) *Kainic Acid as a Tool in Neurobiology*, McGeer, E. G.; Onley, J. W.; McGeer, P. L. (Eds), Raven Press: New York, 1978. (b) Shinozaki, H.; Ishida, M.; Okamoto, T. *Brain Research* **1986**, 399, 395. (c) Watkins, J. M.; Evans, R. H.; Mewett, K. N.; Olverman, H. J.; Pook, P. C. *Excitatory Amino Acid Transmission*, Hicks, T. P.; Lodge, D.; McLennan, H. (Eds), Alan R. Riss Inc: New York, 1987; p 19.
2. Ohfuné, Y.; Tomita, M. *J. Am. Chem. Soc.* **1982**, 104, 3511.
3. James, V. A.; Walker, R. J.; Wheal, H. V. *Br. J. Pharmac.* **1980**, 68, 711.
4. Nakajima, T.; Nomoto, K.; Ohfuné, Y.; Shiratori, Y.; Takemoto, T.; Takeuchi, H.; Watanabe, K. *Br. J. Pharmac.* **1985**, 86, 645.
5. Fowden, L.; Smith, A.; Millington, D. S.; Sheppard, R. C. *Phytochem.* **1969**, 8, 437. We thank Professor Fowden for providing authentic **1a** and **1c**.<sup>6</sup>
6. Kurokawa, N.; Ohfuné, Y. *Tetrahedron Lett.* **1985**, 26, 83. Although we reported the synthesis of *dl*-**1a**, alternative methods were required to prepare of all optically active CCGs **1a-1d** in this study.
7. Ohfuné, Y.; Kurokawa, N. *Tetrahedron Lett.* **1984**, 25, 1071.
8. (a) Sakaitani, M.; Ohfuné, Y. *Tetrahedron Lett.* **1985**, 26, 5543. Instead of *tert*-butyldimethylsilyl trifluoromethanesulfonate, TMSOTf was employed since trimethylsilyl carbamate can be removed during work-up to give the free amine. For acidic conditions, see: (b) Vorbrüggen, H.; Krolikiewicz, K. *Angew. Chem. Int. Ed. Engl.* **1975**, 14, 818.
9. The structures **1a** and **1c** were determined by comparison of their spectroscopic data with those of natural **1a** and **1c**, respectively. Since **7d** formed  $\delta$ -lactone, the structure **1d** can be assigned as depicted. Melting points and  $[\alpha]_D^{25}$  values of **1a**, **1b**, and **1d**. **1a**: mp 243-247 °C (decomp);  $[\alpha]_D^{25}$  +102.0° (c 0.5, H<sub>2</sub>O). **1b**: mp 255-258 °C (decomp);  $[\alpha]_D^{25}$  -20.2° (c 0.51, H<sub>2</sub>O). **1d**: mp 178-180 °C;  $[\alpha]_D^{25}$  +97.1° (c 0.52, H<sub>2</sub>O).
10. All new compounds exhibited satisfactory <sup>1</sup>H NMR, IR, MS, and elementary analytical or HRMS data.
11. The same EPQ ratio of **1a**/erythro-L-BHGA and **1d**/threo-L-BHGA (30/1) suggests the presence of both erythro- and threo-L-BHGA sensitive receptors on PON in a ratio of 10/1 since these EPQ ratio was 10/1.
12. Detailed results of the neurobiological assay related this work, to be published.

(Received in Japan 21 December 1987)